Literature DB >> 6970015

Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass.

A T Culliford, S N Gitel, N Starr, S T Thomas, F G Baumann, S Wessler, F C Spencer.   

Abstract

The activated clotting time (ACT) with a Hemochron system for determining heparin requirements during cardiopulmonary bypass surgery, (CPB) accompanied by hemodilution and hypothermia was evaluated using plasma heparin levels as a standard. In 28 patients who were administered a standard heparin regimen (300 units/kg prebypass, 8000 units in the pump prime and 100 units/kg hourly during CPB) mean prebypass plasma heparin was 4 units/ml, and ACT was 493 seconds. During CPB mean plasma heparin decreased significantly (p < 0.001) to 3.1 units/ml, whereas mean ACT increased significantly (p < 0.001) to 674 seconds. The mean protamine requirement predicted from ACT was significantly higher (43%) than predicted from plasma heparin levels or actual protamine administered. The ACT neither accurately reflected plasma heparin during CPB nor predicted protamine requirements. The fixed-dose regimen employed, however, prevented both intraoperative thrombosis, assessed clinically in all patients, and clotting on six arterial line filters, as determined by scanning EM, despite wide variations in ACT and plasma heparin levels during surgery.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6970015      PMCID: PMC1345010          DOI: 10.1097/00000658-198101000-00017

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  11 in total

1.  Progress report: the activated coagulation time of whole blood (ACT).

Authors:  P G Hattersley
Journal:  Am J Clin Pathol       Date:  1976-11       Impact factor: 2.493

2.  A simple rapid polychrome stain for epoxy-embedded tissue.

Authors:  T Sato; M Shamoto
Journal:  Stain Technol       Date:  1973-09

3.  Statistical correlation and heparin sensitivity of activated partial thromboplastin time, whole blood coagulation time, and an automated coagulation time.

Authors:  H G Schriever; S E Epstein; M D Mintz
Journal:  Am J Clin Pathol       Date:  1973-09       Impact factor: 2.493

4.  Plasma heparin: a unique, practical, submicrogram-sensitive assay.

Authors:  E T Yin; S Wessler; J V Butler
Journal:  J Lab Clin Med       Date:  1973-02

5.  Evaluation of the activated clotting time to control heparin andprotamine dosage in open-heart surgery.

Authors:  C F Arkin; M Shahsavari; B E Copeland; A Kim
Journal:  J Thorac Cardiovasc Surg       Date:  1978-05       Impact factor: 5.209

6.  De-heparinisation of blood after cardiopulmonary bypass.

Authors:  M Hawksley
Journal:  Lancet       Date:  1966-03-12       Impact factor: 79.321

7.  Activated coagulation time of whole blood.

Authors:  P G Hattersley
Journal:  JAMA       Date:  1966-05-02       Impact factor: 56.272

8.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage.

Authors:  B S Bull; W M Huse; F S Brauer; R A Korpman
Journal:  J Thorac Cardiovasc Surg       Date:  1975-05       Impact factor: 5.209

9.  Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols.

Authors:  B S Bull; R A Korpman; W M Huse; B D Briggs
Journal:  J Thorac Cardiovasc Surg       Date:  1975-05       Impact factor: 5.209

10.  Evaluation of the activated whole blood clotting time (ACT) in vitro.

Authors:  S Stenbjerg; E Berg; O K Albrechtsen
Journal:  Scand J Haematol       Date:  1979-09
View more
  16 in total

1.  An evaluation of two activated clotting time monitors during cardiac surgery.

Authors:  D L Reich; K Zahl; M H Perucho; D M Thys
Journal:  J Clin Monit       Date:  1992-01

Review 2.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

3.  Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution.

Authors:  Jorge W Ojito; Robert L Hannan; Michelle Moore Burgos; Hyunsoo Lim; Monique Huynh; Evelio Velis; Marino Arocha; Christopher F Tirotta; Redmond P Burke
Journal:  J Extra Corpor Technol       Date:  2012-03

4.  Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.

Authors:  Peter Hellstern; Juergen Bach; Melanie Simon; Werner Saggau
Journal:  J Extra Corpor Technol       Date:  2007-06

5.  Back to the stacks--looking at classic papers related to the current practice of cardiopulmonary bypass.

Authors:  Joseph J Sistino
Journal:  J Extra Corpor Technol       Date:  2010-12

Review 6.  Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery.

Authors:  Colleen E Gruenwald; Cedric Manlhiot; Lynn Crawford-Lean; Celeste Foreman; Leonardo R Brandão; Brian W McCrindle; Helen Holtby; Ross Richards; Helen Moriarty; Glen Van Arsdell; Anthony K Chan
Journal:  J Extra Corpor Technol       Date:  2010-03

Review 7.  Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.

Authors:  J Bowers; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1993

Review 8.  Coagulation disorders of cardiopulmonary bypass: a review.

Authors:  Domenico Paparella; Stephanie J Brister; Michael R Buchanan
Journal:  Intensive Care Med       Date:  2004-07-24       Impact factor: 17.440

9.  In vitro and in vivo effects of hemodilution on kaolin-based activated clotting time predicted heparin requirement using a heparin dose-response technique.

Authors:  Junko Ichikawa; Satoshi Hagihira; Testu Mori; Mitsuharu Kodaka; Keiko Nishiyama; Makoto Ozaki; Makiko Komori
Journal:  J Anesth       Date:  2016-08-08       Impact factor: 2.078

10.  Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements.

Authors:  Sean Garvin; Daniel C FitzGerald; George Despotis; Prem Shekar; Simon C Body
Journal:  Anesth Analg       Date:  2009-10-27       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.